Intellia Therapeutics Releases Earnings Results, Beats Expectations By 0.03 EPS

NTLA Stock  USD 15.21  0.48  3.26%   
About 64% of all Intellia Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that some traders are interested. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Intellia Therapeutics issued its earnings results on Thursday. The company reported EPS for the quarter, topping the consensus estimate of by 0.03, Briefing.com reports. The firm had revenue of 9.10 million during the quarter, compared to the consensus estimate of 8.28 million. The firms revenue for the quarter

Read at thelincolnianonline.com
news
  

Intellia Therapeutics Current Investor Sentiment

Panic Vs Confidence

64

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.

Intellia Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Intellia Therapeutics Historical Investor Sentiment

Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.

Intellia Therapeutics Fundamental Analysis

We analyze Intellia Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Sales

Price To Sales Comparative Analysis

Intellia Therapeutics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Intellia Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intellia Therapeutics stock to make a market-neutral strategy. Peer analysis of Intellia Therapeutics could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics with similar companies.

Peers

Intellia Therapeutics Related Equities

FATEFate Therapeutics   18.28   
0%
100.0%
CRBUCaribou Biosciences   8.91   
0%
48.0%
VERVVerve Therapeutics   8.85   
0%
48.0%
BEAMBeam Therapeutics   5.26   
0%
28.0%
SANASana Biotechnology   4.08   
0%
22.0%
DNAGinkgo Bioworks   3.90   
0%
21.0%
CRSPCrispr Therapeutics   3.10   
0%
16.0%
EDITEditas Medicine   0.45   
2.0%
0%
VRTXVertex Pharmaceuticals   0.54   
2.0%
0%
PRMEPrime Medicine,   1.20   
6.0%
0%

Complementary Tools for Intellia Stock analysis

When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance